Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
It is time to assess “foreign private issuer” status. Foreign public and private issuers enjoy the benefits of significant exemptions and exclusions from registration under U.S. federal securities laws based on whether they are “foreign private issuers” as defined under the U.S. federal securities laws. The determination of whether issuers satisfy the definition must be made as of the last business day of June for issuers with a December 31 fiscal year end.
Although in 2025 the U.S. Securities and Exchange Commission (SEC) issued a concept release regarding the definition of “foreign private issuer” and whether the SEC should make certain changes to the availability of certain exemptions and exclusions for “foreign private issuers,” as of the date of this client alert, the SEC has not issued any proposed rules around the definition. As such, “foreign private issuer” status should still be assessed under current law. To learn more about the SEC’s concept release, please see our client alert.
The treatment under U.S. federal securities laws of issuers organized in a jurisdiction outside the United States depends upon whether such issuers (both public and private) are considered “foreign private issuers” under the current U.S. definition. This determination will govern, among other things: (1) whether issuers have a U.S. public reporting obligation, and if so, whether they report on foreign forms or domestic forms; and (2) the manner in which they offer their securities both inside and outside the United States.
In most circumstances, under U.S. federal securities laws, issuers must assess their “foreign private issuer” status as of the last business day of their most recently completed second fiscal quarter. For companies with a December 31 fiscal year end, their “foreign private issuer” assessment date falls on Tuesday, June 30, 2026.
The definition of “foreign private issuer” has two parts, and an issuer must fail both parts to not be deemed a “foreign private issuer.” One part of the definition is easier to evaluate, namely whether all of the following are true:
If all of the above are true, then the analysis ceases, and an issuer retains its “foreign private issuer” status.
If any of the above are not true, then the issuer must move to the second part of the test, which requires the issuer to confirm that more than 50% of its outstanding voting securities are not directly or indirectly owned of record by residents of the United States. Although this determination is based on record ownership, an issuer must look through the record ownership of brokers, dealers, banks, and nominees in the United States, its jurisdiction of incorporation, and its primary trading market to the underlying holders to determine whether its U.S. ownership exceeds 50%. This determination generally requires a U.S. and foreign geographic survey to be run as of the last business day of the second fiscal quarter. If more than 50% of the outstanding voting securities are owned of record (determined as described above) by U.S. residents, then “foreign private issuer” status would be lost, and the significant ramifications of losing such status must be considered.
It is important that such analysis be run as of or as close to the last business day of the second fiscal quarter because, for example, Broadridge (which conducts the geographic surveys in Canada and the United States) cannot run this analysis retroactively.
If you have any questions about the test or need assistance in running such test, please contact any of the following partners at Troutman Pepper Locke: Tom Rose at 757.687.7715, Shona Smith at 503.290.2335, or Nicole Edmonds at 202.274.2815.
This just in
Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Speaking Engagements
Performance on Trial: The Construction Manager’s Standard of Care Examined from All Angles
December 2, 2026 | 4:15 PM – 5:30 PM ET
The Hyatt Regency Huntington Beach
Huntington Beach, CA
Speaking Engagements
ACI’s 31st Annual Conference on Drug & Medical Device Litigation – 2026
December 2 – 3, 2026
New York Marriott Marquis
1535 Broadway, New York, NY 10036
Speaking Engagements
Fundamentals of Investment Adviser Regulation 2026
November 19, 2026 | 2:30 PM – 3:30 PM ET
PLI New York
1177 Avenue of the Americas, Entrance on 45th Street, New York, NY 10036